The Danish Medicines Agency initiates its reassessment of the reimbursement status of medicines in ATC group N (Nervous system). It will take place concurrently with the reassessment process for the remaining subgroups in ATC groups A and J.
In 2005, the Danish Parliament decided that the reimbursement status of all medicines must be reassessed on a regular basis. The overall criteria for the prioritisation of the reassessment of the individual groups of medicines are the significance of the medicines to the primary sector and especially general practice, public health aspects, new evidence based recommendations, large expenses for patient and region as well as a large consumption.
On this basis and upon recommendation from the Reimbursement Committee, we will in 2010 begin the reassessment of reimbursement status of the following groups of medicines, in the order mentioned:
- J01, Antibacterials for systemic use
- N06A, Antidepressants
- N02A, Opioids
- A10, Drugs used in diabetes
Simultaneously, we are reassessing the reimbursement status of the remaining subgroups in ATC group A, as we have previously announced. In addition, the Reimbursement Committee will finalise its recommendations for groups C01 and A01.
Status on the process of reassessing the reimbursement status of medicines
In June 2005, we announced that we would begin the reassessment process by reassessing medicines in the three main groups A (Alimentary tract and metabolism), C (Cardiovascular system) and J (Antiinfectives for systemic use), and that we would work on all three groups at the same time.
The status is that group C is nearly completed. Some subgroups of group A are completed, while others are still being assessed. For other groups – like the subgroups of group J – the reassessment has not yet begun. Via the factbox to the right, you can find a list containing a status on the reassessment process and general information on reassessment of the reimbursement status of medicines.
For further information, please contact the Reimbursement Department at email@example.com.
Danish Medicines Agency, 22 December 2009